Retraction of the blood clot by nucleated cells contributes both to hemostasis and to tissue remodeling. Although plasma fibronectin (FN) is a key component of the clot, its role in clot retraction is unclear. In this report, we demonstrate that the incorporation of FN into fibrin matrices significantly improves clot retraction by nucleated cells expressing the integrin ␣ 5 ␤ 1 . Further, we show that FN-fibrin clots support increased cell spreading when compared with fibrin matrices. To determine the structural requirements for FN in this process, recombinant FN monomers deficient in ligand binding or fibrin cross-linking were incorporated into fibrin clots. We show that recombinant FN monomers support clot retraction by Chinese hamster ovary cells expressing the integrin ␣ 5 ␤ 1 . This process depends on both the Arg-Gly-Asp (RGD) and the synergy cell-binding sites and on covalent FN-fibrin binding, demonstrating that cross-linking within the clot is important for cell-FN interactions. These data show that ␣ 5 ␤ 1 can bind to FN within a clot to promote clot retraction and support cell shape change. This provides strong evidence that ␣ 5 ␤ 1 -FN interactions may contribute to the cellular events required for wound contraction.
Following tissue injury or inflammation, the formation of a provisional extracellular matrix (ECM) 1 from extravasated plasma proteins plays a critical role both in hemostasis and wound repair (1, 2) . The principle protein components of this "injury-associated" matrix are fibrin and plasma fibronectin (FN), and in a variety of wound healing events that have been studied, the proteins are deposited together to provide a substrate for cell adhesion and migration (3) . The incorporation of FN into the clot markedly enhances cell attachment to the fibrin matrix (4 -6) . For example, FN is the essential component of plasma clots that facilitates fibroblast migration in vitro (5) . Similarly, it appears to provide a conduit for cell movement from collagen gels into fibrin-rich matrices (6) . Effective cell interaction with FN-fibrin matrices is dependent upon the formation of covalent cross-links between FN and fibrin molecules that are catalyzed by activated factor XIII (7, 8) . For example, Grinnell et al. (9) showed that baby hamster kidney cells required FN and factor XIII for adhesion on fibrin substrates. More recently, using recombinant FN (recFN) molecules that could not be cross-linked to fibrin, we have demonstrated a 50% decrease in cell attachment and spreading on mutant recFN-fibrin matrices when compared with wild type (10) . These data indicate that cross-linking may affect interactions between the adhesive sites of FN and integrin cell surface receptors.
Integrins are the principle mediators of cell interactions with the ECM (11, 12) . They are noncovalently linked heterodimers composed of one ␣ and one ␤ subunit that together determine ligand binding specificity. Evidence suggests that integrins functionally link ECM molecules and cytoskeletal proteins (13) (14) (15) . This allows for the transmission of force by cells to anchorage sites, leading to actin cytoskeletal rearrangements and matrix remodeling (15) . Traction forces generated by nucleated cells can deform three-dimensional matrices composed of collagen or fibrin (16 -18) . The stable exertion of physical force required for gel contraction is dependent on the integrin ␣ subunit and is presumed to reflect the strength of linkages between the integrin cytoplasmic tail and cytoskeletal components (19) . Recently, Chen et al. (20) compared the capacities of two ␤ 3 integrins to mediate fibrin gel retraction by nucleated cells. They demonstrated that ␣ v ␤ 3 but not ␣ IIb ␤ 3 could spontaneously support this process. Similarly, ␣ v ␤ 3 has been shown to induce fibrin clot retraction by a human melanoma cell line (21) . The integrin ␣ 5 ␤ 1 has also been described as a receptor for fibrin clot retraction (22) . Although FN is a ligand for both ␣ v ␤ 3 and ␣ 5 ␤ 1 , a role for FN in clot retraction has not been described.
In the present work, we demonstrate that FN enhances retraction of fibrin matrices by nucleated cells and that this effect is mediated by the integrin ␣ 5 ␤ 1 . Further, we show that FN-fibrin clots support increased cell spreading when compared with fibrin matrices. Finally, we define some of the structural requirements for FN in the process of clot retraction. These data provide strong evidence that in a three-dimensional clot matrix, the engagement of the integrin ␣ 5 ␤ 1 with FN promotes post-receptor occupancy events that include clot retraction and cell shape change. This suggests that ␣ 5 ␤ 1 -FN interactions may play an important role in the early events required for wound remodeling.
EXPERIMENTAL PROCEDURES
Cell Culture-CHO K1 cells transfected with a cDNA to the human ␣ 5 integrin subunit have been previously described (CHO-␣ 5 (26) . Constructions were confirmed by restriction digests. Recombinant protein production was performed as described previously (10) .
Formation and Analysis of FN-Fibrin Clots-Lyophilized human fibrinogen (98.8% clottable, American Diagnostica) and bovine thrombin were reconstituted as described previously (4) . Endogenous human plasma FN contaminating the fibrinogen was removed by batch incubation with gelatin-agarose (4). SDS-polyacrylamide gel electrophoresis, and immunoblotting with an anti-human FN monoclonal antibody was used to monitor the efficiency of FN depletion as previously reported (4). Residual FN was estimated at less than 150 ng of FN/mg of fibrinogen (4) . To assess the cross-linking efficiency of the recFNs versus pFN, the clotting reactions were composed of the following components mixed in a 10:1 physiologic ratio of fibrinogen to FN: fibrinogen 600 g/ml, pFN/recFN 60 g/ml, thrombin 2 units/ml, 0.02 M CaCl 2 , 0.025 M HEPES, pH 7.4, 0.13 M NaCl. Human coagulation factor XIII (Calbiochem-Novabiochem Corp.) was added at 6 g/ml, and the crosslinked products were analyzed as previously reported.
Clot Retraction Assays-24-well tissue culture dishes were coated with 1% bovine serum albumin overnight at 4°C. To prepare fibrin or FN-fibrin clots for retraction assays, the clotting components as described above were mixed in a volume of 0.5 ml at room temperature. CHO-␣ v ␤ 3 (4 ϫ 10 6 /ml) or CHO-␣ 5 ␤ 1 (2 ϫ 10 6 /ml) cells in 0.025 M HEPES, pH 7.4, 0.13 M NaCl were then added to clot components, quickly followed by thrombin. After the addition of thrombin, the mixture was rapidly pipetted into 24-well tissue culture dishes and incubated at 37°C. Aprotinin was added to this system to inhibit fibrinolysis. After 30 min of incubation, 1 ml of Dulbecco's modified Eagle's medium plus 10% FN-depleted FCS was added to the dishes. The clots were then carefully detached from the dishes using a dissecting microscope. Clot retraction was visualized and measured over a 4-h time period using a ruler. The area of the clot was calculated, and the percentage of clot retraction was determined relative to the starting area using the following formula: % retraction ϭ (starting area Ϫ measured area)/starting area ϫ 100.
Cells in three-dimensional matrices were examined using inverted phase contrast optics. Photographic images were captured using an NEC video camera (NEC Corp.) connected to a Macintosh 7100/80 computer equipped with a Scion LG3 image capture board (Scion Corp).
RESULTS

Fibronectin Enhances CHO-␣ v ␤ 3 Retraction of Fibrin Matrices-
The retraction of fibrin matrices by nucleated cells is primarily mediated by the integrin ␣ v ␤ 3 (20, 21) . Because plasma FN is also a ligand for ␣ v ␤ 3 , we sought to determine whether the incorporation of FN into fibrin matrices would affect the ability of cells to retract these matrices. CHO K1 cell transfectants expressing ␣ v ␤ 3 (CHO-␣ v ␤ 3 ) retract fibrin clots (20) . As demonstrated in Fig. 1A , the extent of retraction of FN-fibrin matrices when compared with fibrin matrices was significantly greater at all time points ranging from 30 min to 4 h (p Ͻ .002 at 4 h, Student's unpaired t test). Clot retraction was dependent on cell number as has been demonstrated by others (data not shown).
The ability of cells to exert physical force on three-dimensional substrates has been correlated with cell shape change. For example, cells that have increased capacity to contract collagen matrices display an increased number of cell processes when placed into these gels (19) . To determine whether CHO-␣ v ␤ 3 cells display changes in morphology when cultured in FN-fibrin matrices, cells were seeded in fibrin or FN-fibrin gels and maintained in culture at 37°C. After 18 h, there was a marked increase in the number of spread cells in the FN-fibrin matrices (Fig. 1B) . When clot retraction was measured at 18 h, a significant difference between FN-fibrin and fibrin matrices was observed, comparable with the short time course experiments (data not shown).
Retraction of FN-Fibrin Matrices Is Mediated by Endogenous
The addition of FN to fibrin matrices increases the extent of clot retraction by CHO-␣ v ␤ 3 cells. One possible explanation for this is that FN-␣ v ␤ 3 interactions promote clot retraction. To investigate the contribution of ␣ v ␤ 3 to retraction of FN-fibrin matrices, CHO-␣ v ␤ 3 cells were incubated with a cyclic RGD peptide inhibitor that is specific for ␣ v ␤ 3 at low concentrations (27) . We used the peptide inhibitor rather than function blocking antibodies because others have shown antibodies to be less effective in this context (20) . The effective concentrations of the inhibitor were determined through cell adhesion assays. The peptide at 1 M blocked CHO-␣ v ␤ 3 adhesion to fibrin-or fibrinogen-coated dishes while allowing adherence to FN-coated wells (data not shown). CHO-␣ v ␤ 3 cells in suspension were then incubated in the presence or absence of the peptide inhibitor (1 M) for 30 min at 37°C prior to culture in fibrin matrices. When compared with untreated cells, the presence of the cyclic RGD peptide inhibited clot retraction by an average of 50% ( Fig. 2A) . However, when the CHO-␣ v ␤ 3 cells were cultured in FN-fibrin matrices, there were no significant differences in clot retraction in the presence or absence of the inhibitor (Fig. 2B) . These data strongly suggest that another integrin receptor may have a role in FN-mediated clot retraction.
CHO-␣ v ␤ 3 cells also express endogenous ␣ 5 ␤ 1 , a major FN integrin receptor. To determine whether the integrin ␣ 5 ␤ 1 may be involved in the retraction of FN-fibrin matrices, cells were 6 cells/ml were incubated at 37°C for 30 min following the addition of thrombin to allow clot gelation. Dulbecco's modified Eagle's medium plus 10% FNdepleted FCS was then added, and clots were either detached from the dishes to assay clot retraction (A) or left undisturbed to observe cell morphology (B). Clot retraction was visible and was measured at indicated times. Alternately, cell morphology was examined following overnight incubation, using inverted phase contrast optics. The data in A are expressed as the means Ϯ S.E. of triplicate experiments. preincubated with the hamster-specific anti-␣ 5 ␤ 1 antibody PB-1 and then cultured in fibrin or FN-fibrin gels as described above. Fig. 2B demonstrates that incubation with PB-1 decreases the retraction of FN-fibrin matrices by CHO-␣ v ␤ 3 cells when compared with untreated or cyclic RGD peptide-treated cells. When both the cyclic RGD inhibitor and the PB-1 antibody were present, significant inhibition of clot retraction was achieved for both fibrin and FN-fibrin matrices. These data indicate that nucleated cells can use the ␣ 5 ␤ 1 integrin to promote the retraction of FN-fibrin matrices.
FN-Fibrin Matrices Support ␣ 5 ␤ 1 -mediated Postreceptor Occupancy Events-To establish a role for ␣ 5 ␤ 1 in FN-mediated clot retraction by nucleated cells, CHO K1 cells expressing the human integrin ␣ 5 subunit were used (CHO-␣ 5 ). These cells have the specific advantage of producing little endogenous FN when compared with the parent cells (23) . CHO-␣ 5 cells were cultured in fibrin or FN-fibrin matrices as described above. CHO-␣ 5 cell retraction of FN-fibrin clots was significantly greater than retraction of fibrin clots (Fig. 3 , p Յ .0001 at 4 h; Student's unpaired t test). The extent of retraction was dependent on the concentration of FN. No increase in CHO-␣ 5 cell retraction of fibrin clots was observed when added FN was less than 1.0 g/ml. CHO B2 cells that do not express the ␣ 5 integrin subunit do not retract fibrin or FN-fibrin matrices (data not shown). These data demonstrate that the addition of FN to the fibrin clot markedly improves ␣ 5 ␤ 1 -mediated generation of tractional forces.
Engagement of the ␣ 5 ␤ 1 integrin receptor leads to "postreceptor occupancy" events that have been well described in two-dimensional culture systems (28, 29) . These include cell spreading and intracellular protein tyrosine phosphorylation (30) . However, the cellular events following ␣ 5 ␤ 1 ligation of FN in a three-dimensional culture system have not been described. To examine cell morphology, CHO-␣ 5 cells were seeded in fibrin or FN-fibrin gels and observed in culture at 37°C. By 18 h, it was evident that the incorporation of plasma FN into the fibrin matrix significantly improved cell spreading (Fig. 4) . CHO-␣ 5 cells cultured in FN-fibrin matrices displayed a unique, bipolar cell morphology, whereas those in fibrin matrices remained rounded. Further, CHO-␣ 5 cell retraction of FN-fibrin matrices at 18 h remained significantly greater than retraction of fibrin matrices (data not shown).
Both Plasma FN and Recombinant FN Monomers Promote ␣ 5 ␤ 1 -mediated Clot Retraction-The ␣ 5 ␤ 1 integrin receptor is the primary FN receptor required for the assembly of FN into a fibrillar matrix. Matrix assembly is a process that requires that the FN molecule be in a dimeric form (31) . In a clot, dimeric plasma FN is incorporated into the fibrin matrix. To determine whether the dimer structure is required for FNmediated clot retraction, CHO-␣ 5 cells were cultured in clots formed from fibrin and plasma FN or a recFN M . As indicated in Fig. 3 , the dimeric form of FN is not a requirement for clot retraction.
␣ 5 ␤ 1 -mediated Clot Retraction Requires Both the RGD and Synergy Sites -Our previous work suggests that the covalent incorporation of FN into a fibrin matrix may affect the availability or conformation of integrin-binding sites (4). The ligand requirements for ␣ 5 ␤ 1 -FN interactions have been well described in a two-dimensional system and include the RGD sequence in repeat III 10 and the synergy site in repeat III 9 (11, 12, (32) (33) (34) . The engagement of both sites by the ␣ 5 ␤ 1 integrin receptor is a requirement for full cell adhesion and spreading. To determine the role of these sites in ␣ 5 ␤ 1 -FN interactions in a three-dimensional system, recFN molecules were expressed that contained either a deletion (RGDϪ) or mutation (synϪ) in the important ligand-binding regions. Functional analyses of recFN M polypeptides and equivalent wild type recombinant proteins were performed by assaying clot retraction. In these experiments, CHO-␣ 5 retraction of fibrin matrices served as the negative control, and this background value for clot retraction was subtracted at each time point. When CHO-␣ 5 cells were cultured in FN-fibrin matrices containing recFN M (RGDϪ), clot retraction was decreased by 90% when compared with the wild type recFN M (RGDϩ) (Fig. 5A) . These data demonstrate that the increase in CHO-␣ 5 retraction of FN-fibrin matrices when compared with fibrin matrices is mediated by cell binding to FN. Although CHO-␣ 5 cell retraction of recFN M (synϪ)-fibrin matrices was significantly less than wild type recFN M (synϩ) at all time points (Fig. 5B) , there was still measurable clot retraction. These data suggest that ␣ 5 ␤ 1 engagement of the RGD site can partially support the development of tension by cells that use the ␣ 5 ␤ 1 receptor but that full clot retraction requires the synergy site.
Cross-linking of FN to Fibrin Is Required for Maximal Clot Retraction-Cross-linking of FN to fibrin is required for efficient cell attachment to FN-fibrin matrices (9, 10). To determine whether cross-linking is also required for ␣ 5 ␤ 1 -mediated clot retraction, fibrin clots containing CHO-␣ 5 cells were prepared with either a wild type FN or a mutant recFN lacking the amino-terminal glutamine residues (Gln 3 , Gln 4 , and Gln 16 ) that are important for covalent FN-fibrin interactions (10) . CHO-␣ 5 retraction of fibrin matrices served as the negative control, and this value was subtracted at each time point. Cells cultured in clots composed of the cross-linking-deficient recFN M (Q 3 ) were significantly less efficient in retracting the clot matrices despite the presence of the appropriate ligandbinding site (Fig. 6 ). These data demonstrate that covalent cross-linking of FN to fibrin is required for the maximal promotion of force generation by CHO-␣ 5 cells within the clot.
DISCUSSION
In this report, we have examined whether the covalent incorporation of FN into three-dimensional fibrin clots influences the retraction of these clots by nucleated cells. We demonstrate that FN enhances the retraction of fibrin clots by nucleated cells and that this effect is mediated by the integrin ␣ 5 ␤ 1 . Further, we show that FN-fibrin clots support increased cell spreading when compared with fibrin clots. FN-fibrin clot retraction by ␣ 5 ␤ 1 -expressing cells does not require a dimeric FN molecule. However, retraction does depend on both the RGD and the synergy sites in the cell-binding domain of FN and also requires covalent cross-linking of FN to fibrin. These data provide strong evidence that in a three-dimensional system, the engagement of the integrin ␣ 5 ␤ 1 with FN can contribute to the generation of mechanical force required for clot retraction, leading to distinct changes in cell shape. This suggests that FN may play an important early role in the process of tissue remodeling.
Fibrin clot retraction by both platelets and nucleated cells using receptors of the ␤ 3 integrin family has been described (20, 21, 35) . Integrin ␣ IIb ␤ 3 is essential for platelet-mediated clot retraction but cannot spontaneously support clot retraction in nucleated cells without the presence of an activating antibody (20, 35) . However, nucleated cells that express ␣ v ␤ 3 can retract fibrin matrices (20) . These data support a role for the integrin ␣ subunit cytoplasmic domain in modulating the generation of mechanical force in three-dimensional substrates. This has also been observed in a collagen gel system using chimeric ␣ 2 integrin subunits composed of the external and transmembrane domains of ␣ 2 coupled to the cytoplasmic domains of ␣ 5 (19) . The chimeric ␣ 2 -␣ 5 ␤ 1 complex had similar function to ␣ 2 ␤ 1 in mediating collagen gel retraction, demonstrating that the integrin ␣ 5 cytoplasmic tail can influence the generation of tension.
Plasma FN is a key adhesive component of the fibrin-rich matrices typically found at injury sites, and with a plasma concentration of 330 g/ml, it seems likely that FN is deposited wherever fibrinous exudates occur (3) . Further, the release of FN from activated platelets may contribute to the dispersal of FN throughout the clot. Although a role for FN in cell adhesion and migration has been well described, a contribution to clot retraction has not been determined. Our results demonstrate a consistent increase in the ability of the CHO-␣ v ␤ 3 cells to retract FN-fibrin matrices when compared with fibrin matrices. This response resulted from an interaction between endogenous hamster ␣ 5 ␤ 1 and FN. One explanation for these observations could be that the engagement of additional integrin receptors strengthens the mechanical link between the ECM and the cytoskeleton by increasing the total number of receptor-ECM connections. In this instance, ␣ 5 ␤ 1 and ␣ v ␤ 3 would be functionally equivalent in their ability to mediate gel retraction. However, our data suggest that ␣ 5 ␤ 1 plays the major role in mediating FN-dependent clot retraction. This is indicated by the fact that the cyclic peptide has a limited ability to inhibit FN-mediated clot retraction in the presence of functioning ␣ 5 ␤ 1 . Previous work has suggested that ␣ 5 ␤ 1 can exclude other FN integrins from particular functions. For example, Wennerberg et al. (36) showed that ␤ 1 -null cells that express ␣ v ␤ 3 were capable of assembling a FN matrix. However, when these cells were transfected with a ␤ 1 subunit and expressed functional ␣ 5 ␤ 1 , ␣ v ␤ 3 was excluded from sites of FN matrix assembly, suggesting that ␣ 5 ␤ 1 assumed a preferential role in this process. Similarly, the presence of ␣ 5 ␤ 1 can exclude ␣ v ␤ 1 from sites of cell-FN attachment (37) .
It is possible that the ␣ 5 ␤ 1 -FN interactions leading to the generation of mechanical force in a three-dimensional matrix may be comparable with those required for FN matrix assembly. In this context, therefore, the ␣ 5 ␤ 1 integrin may preferentially trigger post-receptor occupancy events that promote force generation with greater efficiency than ␣ v ␤ 3 and thus exclude it from the process. Differences in the abilities of individual integrins to support tractional forces have been demonstrated. Interestingly, an inverse correlation has been reported between the ability of cells expressing specific integrins to generate tension and their rates of cell migration (19, 38) . For example, transfectants that expressed chimeric ␣ 2 integrin subunits composed of the external and transmembrane domains of ␣ 2 coupled to the cytoplasmic domains of ␣ 2 , ␣ 5 , or ␣ 4 were examined for their migratory rates on collagen (19) . Cells that expressed the ␣ 2 /␣ 4 chimera had the fastest migratory rate but the least capacity to contract collagen matrices. In contrast, the ␣ 2 /␣ 5 chimera had a relatively low migratory rate but an increased capacity to retract collagen gels. Because the ␣ v ␤ 3 integrin is also thought to play a key role in cell migration events (40, 41) , this integrin may be less effective than ␣ 5 ␤ 1 in FN-mediated clot retraction.
Recently, ␣ 5 ␤ 1 has been shown to bind to fibrin, both in twoand three-dimensional systems (22, 42) . CHO-␣ 5 transfectants retract fibrin matrices, but the addition of FN even at low concentrations increases clot retraction 2-to 3-fold. Cross-linking of FN to fibrin increases fibrin fibril thickness and strength (43, 44) . These changes could alter fibrin structure, making it a more efficient ligand for ␣ 5 ␤ 1 . When the retraction of recFNfibrin matrices composed of recFN M (RGDϩ) and recFN M (RGDϪ) are examined, however, CHO-␣ 5 retraction of the recFN M (RGDϪ)-fibrin matrix is comparable with fibrin alone, demonstrating that the increased clot retraction results from the ligation of ␣ 5 ␤ 1 by FN specifically. Furthermore, FN-fibrin matrices support distinct cell shape change. It is possible that the ␣ 5 ␤ 1 -mediated promotion of clot retraction may occur via the establishment of a functional link between FN and the cytoskeleton mediated by ␣ 5 ␤ 1 that supports the generation of mechanical force. In two-dimensional systems, ␣ 5 ␤ 1 -FN interactions result in the assembly of FN into a fibrillar matrix, organization of the cytoskeleton into stress fibers, and distinct intracellular signaling events (23, 32) . However, it is also possible that ␣ 5 ␤ 1 -FN interactions could influence clot retraction via "inside-out" signaling events that may impact other integrin receptors.
The differences in the ability of ligands to promote postreceptor occupancy events may depend on the mechanism through which they occupy the ligand-binding pocket of ␣ 5 ␤ 1 . Recent evidence suggests that cells can sense the rigidity of the ECM and respond by localized strengthening of cytoskeletal linkages (45) . This process of reinforcement required occupancy of FN-binding sites and could not be duplicated by antibody cross-linking of the integrin receptors. Thus, it is possible that a ligand that does not effectively occupy the ␣ 5 ␤ 1 -binding site permits only limited strengthening of the cytoskeletal attachments and incomplete force generation. In a three-dimensional matrix, therefore, fibrin may not effectively occupy the ligandbinding site of ␣ 5 ␤ 1 . Thus, integrin-cytoskeletal linkages are not reinforced limiting the strength of cell-ECM contacts that are required for clot retraction and cell shape change. This model also provides an attractive explanation for why the synergy site is required for efficient FN-fibrin matrix retraction, because in its absence, the ligand-binding pocket of ␣ 5 ␤ 1 is only partially occupied.
There also may be a relationship between ECM rigidity and the generation of force at anchorage sites. This suggests a mechanism that explains the importance of cross-linking in FN-mediated clot retraction. In the absence of cross-linking, we observed a nearly 75% decrease in clot retraction. The generation of traction forces by cells requires that the ECM resist cell tension at attachment sites (45, 46) . Perhaps, if FN molecules are not fixed in position by the cross-linking process, they "give" in response to applied mechanical stress. As a result, cells maintain a more rounded configuration, and the cytoskeletal rearrangements required for force generation are not achieved.
In summary, we have demonstrated that the incorporation of FN into fibrin matrices significantly improves clot retraction by nucleated cells and that this effect is mediated by the integrin ␣ 5 ␤ 1 . Further, we show that FN-fibrin clots support increased cell spreading when compared with fibrin matrices. Finally, we have determined that both the RGD and synergy sites in FN, as well as the covalent incorporation of FN into the fibrin matrix are required for ␣ 5 ␤ 1 -mediated promotion of clot retraction. These data provide strong evidence that ␣ 5 ␤ 1 -FN interactions in a three-dimensional clot matrix may contribute to the events required for early tissue remodeling.
